MISRII

Creative Biolabs offers a cutting-edge and innovative selection of anti-MISRII CAR-T products and services for global customers. Please browse the following list to find the appropriate products for you.

Background

MISRII, also known as the anti-Müllerian hormone type II receptor (AMHR2), belongs to the transforming growth factor b (TGF-b) receptor family and plays a crucial role in the regression of the Müllerian ducts during male embryo development. The ligand for MISRII, Müllerian inhibiting substance (MIS), triggers a signaling cascade that induces cell cycle arrest and apoptosis. In cancer, MISRII is significantly overexpressed in epithelial ovarian cancers, endometrial carcinomas, and other gynecologic malignancies, offering a specific target for therapeutic interventions.

Associated Diseases

• Ovarian Cancer
• Gynecologic Malignancies
• Endometrial carcinomas

Anti-MISRII CAR-T Services

Anti-MISRII CAR-T In Vitro Assays

• Anti-MISRII CAR Construct Design

Regarding the CAR design and construction, Creative Biolabs has developed a user-friendly CAR design system for global customers to custom their desired CAR constructs.

Fig.1 Schematic representation of MISRII CAR construction.¹

• Anti-MISRII CAR-T Expression Test

Creative Biolabs offers various CAR detection reagents and expression tests to confirm the presence of CARs on engineered T cells.

Fig.2 Surface MISRII CAR expression in primary human T cells after CAR transduction.¹

• Anti-MISRII CAR-T Cytokine Release Test

The cytokine release testing illustrates the specificity and effectiveness of CART cells for target cells, providing more information about the functional properties of the CAR-T cells and their interaction with the tumor microenvironment. Creative Biolabs utilizes multiple cytokine tests to comprehensively assess the cytokine release profile of anti- MISRII CAR-T cells, such as intracellular cytokine staining test, and multiple cytokine arrays.

Fig.3 Intracellular cytokine staining detection of different anti-MISRII CAR-T co-culture with target cells.1

• Anti-MISRII CAR-T In Vitro Cytotoxicity Assay

The in vitro cytotoxicity assay helps in determining the efficacy of anti- MISRII CAR-T cells against MISRII-expressing tumor cells, guiding the development and optimization of the therapy. Creative Biolabs has launched various methods to test in vitro cytotoxicity for anti-MISRII CAR-T, including but not limited to: LDH cytotoxicity test, flow cytometry cytotoxicity test, and real-time dynamic cytotoxicity analysis.

Fig.4 The tumor killing activity of anti-MISRII (GM7) CAR-T against C30.MISIIR target cells by real-time cytotoxicity assays.¹

Anti-MISRII CAR-T In Vivo Assays

• Anti-MISRII CAR-T Cell Therapy Animal Models

The choice of an appropriate animal model is crucial in assessing the efficacy of anti-MISRII CAR-T therapy in vivo. Different models, such as xenograft, humanized, syngeneic, and transgenic models, provide unique insights into various aspects of CAR-T cell therapy. Xenograft models, for instance, involve injecting immunocompromised mice with human tumor cells to assess the antitumor activity of anti-MISRII CAR-T cells.

• Efficacy Test of Anti-MISRII CAR-T

Creative Biolabs provides a robust platform for evaluating the therapeutic potential of anti-MISRII CAR-T cells in the context of cancer treatment. Through meticulous study design, precise evaluation of antitumor activity, and rigorous safety assessments, researchers can gain valuable insights into the efficacy and safety profile of anti-MISRII CAR-T therapy, paving the way for potential clinical applications in combating MISRII-expressing malignancies.

Fig.5 The antitumor activity of the anti-MISRII (GM7) CAR-T cells in C30.MISIIR GFP-fLuc cells engrafted NSG mouse model.¹

Reference

1. Rodriguez-Garcia, Alba, et al. "CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic malignancies." Molecular Therapy 28.2 (2020): 548-560.